Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s share buyback program ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

(RTTNews) - Sanofi announced the acquisition of 2.3% of its shares from L'Oréal. This transaction is part of share buyback program announced on January 30, 2025. This will involve the acquisition ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

The Food and Drug Administration has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility in Massachusetts where the company makes ...

Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for t ...

French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an inspection at its drug manufacturing facility in Framingham. French ...

Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a trial designed to test an over-the-counter version of its erectile ...